UPCC 11220: BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
The study will enrollsubjects who have undergone surgery for stage II or III colorectal cancer and who have residual FFPE tissue available will provide FFPE and whole blood samples. Subjects will receive SIGNATERA test results and may be recommended for adjuvant chemotherapy or observation by their treating clinician.The study also has a control arm of matched Stage II or Stage III colorectal cancer cases that have a minimum of least 2 years clinical follow-up data.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 843763
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
